Chorioallantoic urothelial tumor avatar. A clinical tool for phenotype-based therapy.

Abstract excerpt

In the muscle invasive bladder cancer (MIBC) standard of care treatment only patients presenting a major pathological tumor response are more likely to show the established modest 5% absolute survival benefit at 5 years after cisplatin-based neoadjuvant chemotherapy (NAC). To overcome the drawbacks of a blind NAC (i.e. late cystectomy with unnecessary NAC adverse events) with potential to survival improvements,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Carcinoma
• Share to Neoadjuvant Therapy